One Curegen

One Curegen is a South Korea-based private oncology biotechnology company developing companion diagnostic-guided anticancer therapeutics. The company was formed in 2020 as a joint venture involving the Korea Research Institute of Bioscience and Biotechnology and iCure, combining cancer peptide discovery with drug delivery know-how. Its work appears focused on biomarker discovery and validation, targeted treatment selection, and novel anticancer agents for difficult-to-treat and rare cancers, particularly gastric cancer. Publicly visible pipeline information suggests a preclinical portfolio spanning peptide, small-molecule, and PROTAC-related programs against targets including VGLL1, HIF-1α, and SYT11. The company is best characterized as an early-stage platform oncology biotech rather than a clinical-stage drug developer.